Edwards Lifesciences Co. (NYSE:EW) Stock Position Lifted by BNP Paribas Arbitrage SA

BNP Paribas Arbitrage SA boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 22.4% during the second quarter, HoldingsChannel.com reports. The firm owned 366,508 shares of the medical research company’s stock after acquiring an additional 67,183 shares during the period. BNP Paribas Arbitrage SA’s holdings in Edwards Lifesciences were worth $37,959,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in EW. Miracle Mile Advisors LLC lifted its stake in shares of Edwards Lifesciences by 9.3% in the second quarter. Miracle Mile Advisors LLC now owns 9,053 shares of the medical research company’s stock worth $938,000 after buying an additional 767 shares during the last quarter. Sarasin & Partners LLP lifted its stake in shares of Edwards Lifesciences by 25.9% in the second quarter. Sarasin & Partners LLP now owns 254,535 shares of the medical research company’s stock worth $26,362,000 after buying an additional 52,386 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Edwards Lifesciences in the first quarter worth $48,439,000. Peregrine Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 4.8% in the second quarter. Peregrine Capital Management LLC now owns 447,578 shares of the medical research company’s stock worth $46,356,000 after buying an additional 20,564 shares during the last quarter. Finally, Standard Life Aberdeen plc lifted its stake in shares of Edwards Lifesciences by 4.3% in the first quarter. Standard Life Aberdeen plc now owns 234,235 shares of the medical research company’s stock worth $19,591,000 after buying an additional 9,644 shares during the last quarter. 80.13% of the stock is currently owned by hedge funds and other institutional investors.

In other Edwards Lifesciences news, VP Larry L. Wood sold 7,830 shares of the firm’s stock in a transaction on Monday, July 12th. The stock was sold at an average price of $107.48, for a total transaction of $841,568.40. Following the completion of the sale, the vice president now owns 379,964 shares of the company’s stock, valued at approximately $40,838,530.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Huimin Wang sold 6,350 shares of the firm’s stock in a transaction on Thursday, July 8th. The shares were sold at an average price of $106.72, for a total value of $677,672.00. Following the sale, the vice president now directly owns 104,377 shares of the company’s stock, valued at approximately $11,139,113.44. The disclosure for this sale can be found here. Insiders have sold a total of 96,530 shares of company stock valued at $11,055,715 over the last ninety days. Company insiders own 1.35% of the company’s stock.

NYSE EW opened at $120.94 on Wednesday. The business has a 50 day simple moving average of $113.85 and a 200 day simple moving average of $99.42. Edwards Lifesciences Co. has a 52-week low of $70.92 and a 52-week high of $123.27. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.89 and a current ratio of 3.75. The stock has a market cap of $75.39 billion, a price-to-earnings ratio of 51.91, a PEG ratio of 3.40 and a beta of 1.08.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 29th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.09. Edwards Lifesciences had a return on equity of 29.73% and a net margin of 29.69%. The business had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.29 billion. On average, analysts predict that Edwards Lifesciences Co. will post 2.26 EPS for the current year.

A number of equities analysts recently issued reports on EW shares. Jefferies Financial Group boosted their target price on shares of Edwards Lifesciences from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, July 30th. Canaccord Genuity boosted their target price on shares of Edwards Lifesciences from $103.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, July 30th. SVB Leerink boosted their price target on shares of Edwards Lifesciences from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Friday, July 30th. Credit Suisse Group boosted their price target on shares of Edwards Lifesciences from $112.00 to $126.00 and gave the company an “outperform” rating in a report on Friday, July 30th. Finally, Piper Sandler boosted their price target on shares of Edwards Lifesciences from $105.00 to $120.00 and gave the company an “overweight” rating in a report on Tuesday, July 27th. Eight investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Buy” and an average price target of $116.33.

About Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.

Featured Story: Intrinsic Value

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.